Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabet Størset

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|February 2, 2017
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantationElisabet Størset, Kristine Hole, Karsten Midtvedt, et al.
British Journal of Clinical Pharmacology|August 4, 2015
Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid doseChristine E Staatz, Elisabet Størset, Troels K Bergmann, et al.
European Journal of Clinical Pharmacology|September 28, 2013
Importance of hematocrit for a tacrolimus target concentration strategyElisabet Størset, Nick Holford, Karsten Midtvedt, et al.
British Journal of Clinical Pharmacology|December 24, 2016
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearanceElisabet Størset, Kristine Hole, Karsten Midtvedt, et al.
British Journal of Clinical Pharmacology|April 5, 2017
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'Elisabet Størset, Kristine Hole, Karsten Midtvedt, et al.
European Journal of Clinical Pharmacology|February 22, 2023
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotypeBirgit M Wollmann, Elisabet Størset, Marianne Kristiansen Kringen, et al.
Therapeutic Drug Monitoring|February 25, 2025
The Effect of Age on Antipsychotic Serum Concentration in Males and Females: A Study Based on Therapeutic Drug Monitoring Data From 19,926 PatientsVigdis Solhaug, Ragnhild Birkeland Waade, Espen Molden, et al.
Ebiomedicine|August 28, 2023
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients - a study based on a cohort of 19,742 patientsPari Faraj, Elisabet Størset, Kristine Hole, et al.
Transplantation|April 19, 2015
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized StudyElisabet Størset, Anders Åsberg, Morten Skauby, et al.
Therapeutic Drug Monitoring|March 29, 2016
Prediction of Fat-Free Mass in Kidney Transplant RecipientsElisabet Størset, Marit Elizabeth von Düring, Kristin Godang, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|February 2, 2017
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantationElisabet Størset, Kristine Hole, Karsten Midtvedt, et al.
British Journal of Clinical Pharmacology|August 4, 2015
Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid doseChristine E Staatz, Elisabet Størset, Troels K Bergmann, et al.
European Journal of Clinical Pharmacology|September 28, 2013
Importance of hematocrit for a tacrolimus target concentration strategyElisabet Størset, Nick Holford, Karsten Midtvedt, et al.
British Journal of Clinical Pharmacology|December 24, 2016
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearanceElisabet Størset, Kristine Hole, Karsten Midtvedt, et al.
British Journal of Clinical Pharmacology|April 5, 2017
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'Elisabet Størset, Kristine Hole, Karsten Midtvedt, et al.
European Journal of Clinical Pharmacology|February 22, 2023
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotypeBirgit M Wollmann, Elisabet Størset, Marianne Kristiansen Kringen, et al.
Therapeutic Drug Monitoring|February 25, 2025
The Effect of Age on Antipsychotic Serum Concentration in Males and Females: A Study Based on Therapeutic Drug Monitoring Data From 19,926 PatientsVigdis Solhaug, Ragnhild Birkeland Waade, Espen Molden, et al.
Ebiomedicine|August 28, 2023
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients - a study based on a cohort of 19,742 patientsPari Faraj, Elisabet Størset, Kristine Hole, et al.
Transplantation|April 19, 2015
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized StudyElisabet Størset, Anders Åsberg, Morten Skauby, et al.
Therapeutic Drug Monitoring|March 29, 2016
Prediction of Fat-Free Mass in Kidney Transplant RecipientsElisabet Størset, Marit Elizabeth von Düring, Kristin Godang, et al.
Pageof 3